We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-4.06%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$225M
AUM Growth
+$33.3M
Cap. Flow
+$42.3M
Cap. Flow %
18.83%
Top 10 Hldgs %
56.68%
Holding
48
New
12
Increased
15
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.6M
2
THOR
THORATEC CORPORATION
THOR
+$12M
3
ACHV icon
Achieve Life Sciences
ACHV
+$11.8M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$9.18M
5
ARDM
Aradigm Corp Common Stock
ARDM
+$9.11M

Top Sells

Rank Stock Value
1
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$17.9M
2
FLNA
Filana Therapeutics
FLNA
+$3.13M
3
PLX icon
Protalix BioTherapeutics
PLX
+$3M
4
CYTK icon
Cytokinetics
CYTK
+$2.99M
5
NSPH
NANOSPHERE INC. COM NEW
NSPH
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 74.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$16.8B
$22.4M 9.98%
1,512,103
+892,103
+144% +$12.6M
HPTX
2
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$17.2M 7.64%
657,984
+164,233
+33% +$4.22M
DSCI
3
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$13.3M 5.9%
1,148,292
+223,292
+24% +$2.29M
THOR
4
DELISTED
THORATEC CORPORATION
THOR
$12.6M 5.58%
+360,000
New +$12M
INFI
5
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$12.2M 5.43%
958,600
+458,200
+92% +$4.77M
OFIX icon
6
Orthofix Medical
OFIX
$477M
$10.9M 4.85%
300,700
+50,700
+20% +$1.64M
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$10.6M 4.71%
+250,100
New +$9.18M
FLNA
8
Filana Therapeutics
FLNA
$48.8M
$9.74M 4.33%
242,037
-84,717
-26% -$3.13M
ALIM
9
DELISTED
Alimera Sciences
ALIM
$9.63M 4.28%
107,354
+7,354
+7% +$653K
ARDM
10
DELISTED
Aradigm Corp Common Stock
ARDM
$8.92M 3.97%
+1,008,062
New +$9.11M
TENX icon
11
Tenax Therapeutics
TENX
$363M
$8.63M 3.84%
66
+3
+5% +$463K
VCYT icon
12
Veracyte
VCYT
$3.7B
$7.9M 3.51%
461,210
+150,962
+49% +$2.17M
ACHV icon
13
Achieve Life Sciences
ACHV
$659M
$7.88M 3.5%
+960
New +$11.8M
AMBI
14
DELISTED
Ambit Biosciences Corp
AMBI
$7.28M 3.24%
1,053,895
+334,634
+47% +$2.35M
ARCT icon
15
Arcturus Therapeutics
ARCT
$164M
$5.76M 2.56%
47,558
+5,614
+13% +$678K
ANTH
16
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.08M 2.26%
187,500
+16,345
+10% +$403K
EXAS
17
PUT
DELISTED
Exact Sciences
EXAS
$4.27M 1.9%
+250,900
New +$3.45M
AVEO
18
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.25M 1.89%
232,500
-54,148
-19% -$704K
SCTL
19
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.17M 1.86%
580,665
-66,035
-10% -$401K
VOLC
20
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$4.1M 1.82%
232,645
-67,355
-22% -$1.23M
SPHS
21
DELISTED
Sophiris Bio, Inc.
SPHS
$3.55M 1.58%
1,585,500
+85,500
+6% +$253K
KPTI icon
22
Karyopharm Therapeutics
KPTI
$43.5M
$3.49M 1.55%
+5,000
New +$2.33M
TVRD
23
Tvardi Therapeutics
TVRD
$19.7M
$3.41M 1.52%
5,562
+616
+12% +$332K
CUTR
24
DELISTED
Cutera, Inc.
CUTR
$3.16M 1.4%
+303,713
New +$3.08M
ELGX
25
DELISTED
Endologix Inc
ELGX
$2.94M 1.31%
+19,328
New +$2.57M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2014 Portfolio in Review

As of Q2 2014, Great Point Partners held 48 positions worth $225M, up 17% from $191M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners deployed $42.3M of net new capital in Q2 2014, opening 12 new positions and adding to 15 existing holdings. Its largest new stake was THORATEC CORPORATION: 360,000 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 67% a quarter earlier.

On the sell side, the largest reduction was Filana Therapeutics, an estimated $3.13M trimmed.

  • Great Point Partners's largest Q2 2014 buy was THORATEC CORPORATION: 360,000 shares worth $12.6M.
  • Great Point Partners added most to Neurocrine Biosciences in Q2 2014, an estimated $12.6M increase.
  • Great Point Partners's biggest Q2 2014 reduction was Filana Therapeutics, cutting an estimated $3.13M.
  • Great Point Partners fully exited FURIEX PHARMACEUTICALS INC COM STK (DE) in Q2 2014, selling an estimated $17.9M.
  • Great Point Partners's ten largest holdings make up 57% of its $225M portfolio in Q2 2014.
  • Great Point Partners opened 12 new positions and closed 10 in Q2 2014.
  • Great Point Partners's portfolio value rose 17% quarter-over-quarter to $225M.

Based on Great Point Partners's 13F filing for Q2 2014, filed 14 Aug 2014.